


CLAIM AMENDMENTS:


This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A crystalline ethyl acetate solvate solid of carvedilol characterized by data selected from the group consisting of a PXRD pattern with peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta, a DSC thermogram with endothermic peaks at about 74° C. and 112° C., and a FTIR spectrum with peaks at about 613, 740, 994, 1125, 1228, 1257, 1441, 1508, 1737, 2840, 3281, 3389, and 3470 cm^{-1} .
2. (currently amended) ~~The~~ A crystalline ethyl acetate solvate of carvedilol of claim 1 characterized by a PXRD pattern having peaks at about 6.5, 7.3, 16.0, and 30.5 ± 0.2 degrees two-theta.
3. (currently amended) The crystalline ethyl acetate solvate of carvedilol of claim 2 further characterized by the PXRD pattern having peaks at about 5.8, 10.7, 11.1, 11.5, 13.1, 13.7, 16.8, 17.7, 18.5, and 23.0 ± 0.2 degrees two-theta.
4. (currently amended) The crystalline ethyl acetate solvate of carvedilol of claim 3 ~~characterized by a~~ wherein the PXRD pattern substantially as follows:



5. (currently amended) The crystalline ethyl acetate solvate of carvedilol of claim 1 2 characterized by a DSC thermogram having peaks at about 74° C. and 112° C.


6. (currently amended) The crystalline ethyl acetate solvate of carvedilol of claim 5 characterized by a wherein the DSC thermogram is substantially as follows:



7. (currently amended) The crystalline ethyl acetate solvate of carvedilol of claim 6 further characterized by a FTIR spectrum having peaks at about 613, 740, 994, 1125, 1228, 1257, 1441, 1508, 1737, 2840, 3281, 3389, and 3470 cm^{-1} .

8. (currently amended) The crystalline ethyl acetate solvate of carvedilol of claim 7 further characterized by the FTIR spectrum having peaks at about 720, 1100, 1286, 1454, 1589, 2911, and 2935 cm^{-1} .

9. (currently amended) The crystalline ethyl acetate solvate of carvedilol of claim 8 ~~characterized by a~~ wherein the FTIR spectrum is substantially as follows:



10. (currently amended) ~~Crystalline~~ The crystalline ethyl acetate solvate of carvedilol Form VI of claim 2 further characterized by a Differential Thermal Gravimetry thermogram showing a weight loss step in the temperature range of 35 to 104° C of about 13%.

11-17. (canceled)

18. (currently amended) A pharmaceutical composition comprising an effective amount of ~~the a crystalline ethyl acetate solvate solid of carvedilol of claim 1~~ characterized by data selected from the group consisting of a PXRD pattern with peaks at about 6.5, 7.3, 16.0, and 30.5±0.2 degrees two-theta, a DSC thermogram with endothermic peaks at about 74° C. and 112° C., and a FTIR spectrum with peaks at about 613, 740, 994, 1125, 1228, 1257, 1441, 1508, 1737, 2840, 3281, 3389, and 3470 cm⁻¹ and at least one pharmaceutically acceptable excipient.


19. (original) A pharmaceutical dosage form comprising the pharmaceutical composition of claim 18.

20. (original) The pharmaceutical dosage form of claim 19 wherein the dosage form is an oral dosage form.

21. (original) The pharmaceutical dosage form of claim 20 wherein the oral dosage form is a capsule or tablet.

22-27. (canceled)

28. (New) The ethyl acetate solvate of carvedilol of claim 10, wherein the Differential Thermal Gravimetry thermogram is substantially as follows:



29. (New) The ethyl acetate solvate of carvedilol of claim 2 free of water when tested by Karl-Fisher titration.